Does Systemic Metformin Have a Role in Treating Melasma?
Dermatol Surg
; 50(4): 366-371, 2024 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-38416809
ABSTRACT
BACKGROUND:
Melasma is a common pigmentary condition that affects the patients' quality of life and all the prescribed treatment options till now are not satisfactory, especially in dark-skinned patients.OBJECTIVE:
To evaluate the efficacy and safety of systemic metformin (1,000 mg and 500 mg) combined with trichloroacetic acid (TCA) peeling versus TCA alone in the treatment of melasma. PATIENTS ANDMETHODS:
The study included 60 melasma patients divided into 3 groups Group A received systemic metformin (1000 mg/d), Group B received systemic metformin (500 mg/d) and Group C received placebo. The 3 treatment groups were treated by TCA 25% over the whole face bimonthly for a total of 6 sessions. Melasma area and severity index (MASI), and Melasma impact Quality of life Scale (MELASQOL) were used to assess the outcome.RESULTS:
There was a statistically significant decrease in the MASI, and the MELASQOL in the 3 studied groups after treatment with significantly better improvement in Group (A) than Group (C) ( p = .045).CONCLUSION:
Systemic metformin is a safe and promising therapeutic option for treating melasma.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Abrasão Química
/
Melanose
Limite:
Humans
Idioma:
En
Revista:
Dermatol Surg
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Egito